ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,309.53
      1.20%
      US Tech 100
      18,113.00
      1.55%
      Dow Jones
      39,915.68
      0.90%
      Brent Oil
      82.74
      0.23%
      Bitcoin
      66,011.78
      7.25%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. UK
      5. LSE
      6. Galapagos (GLPG)

      7. Galapagos (GLPG) News

      GLPG

      Galapagos (GLPG)

      Galapagos
      		Date:
      Sort by:
       Showing the most relevant articles for your search:LSE:GLPG
      DateTimeSourceHeadlineSymbolCompany
      2:30PMiHub NewswireFeaturedIntegrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share
      02/22/20244:01PMUK RegulatoryGalapagos announces full year 2023 results and outlook for 2024LSE:GLPGGalapagos
      02/15/20244:01PMUK RegulatoryGalapagos presents at EBMT-EHA annual meeting 2024LSE:GLPGGalapagos
      01/31/20244:01PMUK RegulatoryGalapagos completes transaction to transfer Jyseleca® business to AlfasigmaLSE:GLPGGalapagos
      05/06/20151:31AMGlobeNewswireGalapagos listed 10 years on Euronext Amsterdam and BrusselsLSE:GLPGGalapagos
      05/06/20151:31AMGlobeNewswireGalapagos announces launch of proposed global offeringLSE:GLPGGalapagos
      05/01/201512:00PMGlobeNewswireBNP Paribas notify of 4.8% shareholding in GalapagosLSE:GLPGGalapagos
      05/01/201512:00PMGlobeNewswireGalapagos creates new warrant planLSE:GLPGGalapagos
      04/27/20154:00PMGlobeNewswireFilgotinib as monotherapy also hits primary endpoint in DARWIN 2 trialLSE:GLPGGalapagos
      04/15/20155:00PMGlobeNewswireGalapagos files registration statement in the United States for a proposed global offeringLSE:GLPGGalapagos
      04/14/20154:00PMGlobeNewswireGalapagos' JAK1 inhibitor filgotinib (GLPG0634) meets primary and other key efficacy endpoints after 12 weeks of treatment in...LSE:GLPGGalapagos
      03/27/20152:29PMGlobeNewswirePublication of Annual Report 2014 and invitation to the Annual Shareholders' Meeting to be held on 28 April 2015LSE:GLPGGalapagos
      03/27/20152:30AMGlobeNewswireGalapagos raises €5.8 million through warrant exercises, Board and Executive Committee members investLSE:GLPGGalapagos
      03/17/20152:31AMGlobeNewswireGalapagos regains rights to GLPG1690, announces end of alliance with JanssenLSE:GLPGGalapagos
      03/06/20151:35AMGlobeNewswireGalapagos to be included in Amsterdam Midcap IndexLSE:GLPGGalapagos
      03/06/20151:31AMGlobeNewswireGalapagos reports 2014 financial resultsLSE:GLPGGalapagos
      02/23/20151:30AMGlobeNewswireGalapagos reports that the last patient in DARWIN 1 has completed 12 weeks of treatmentLSE:GLPGGalapagos
      02/16/20151:30AMGlobeNewswireGalapagos reports positive Phase 1 results for GLPG1690LSE:GLPGGalapagos
      02/11/20151:31AMGlobeNewswireGalapagos receives €1.6 million IWT grant for hepatitis B programLSE:GLPGGalapagos
      02/09/20151:31AMGlobeNewswireBNP Paribas notify of 5.08% shareholding in GalapagosLSE:GLPGGalapagos
      01/22/20151:31AMGlobeNewswireGalapagos receives €2.5 million IWT grant for antibiotic researchLSE:GLPGGalapagos
      01/21/201512:56PMGlobeNewswireDelta Lloyd notify of 4.96% shareholding in GalapagosLSE:GLPGGalapagos
      01/09/20151:30AMGlobeNewswireVicki Sato resigns from Galapagos BoardLSE:GLPGGalapagos
      01/08/20151:30AMGlobeNewswireGalapagos starts Phase 2 trial with GLPG1205 in ulcerative colitis patientsLSE:GLPGGalapagos
      12/19/20141:31AMGlobeNewswireGalapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbVieLSE:GLPGGalapagos
      12/16/20141:32AMGlobeNewswireGalapagos regains full rights to GPR84 inhibitor GLPG1205LSE:GLPGGalapagos
      12/12/20141:31AMGlobeNewswireGalapagos selects second component of its investigational cystic fibrosis combination treatmentLSE:GLPGGalapagos
      08/08/20141:30AMGlobeNewswireGalapagos cash position of €232 M provides solid basis for R&D pipeline investmentLSE:GLPGGalapagos
      08/05/20141:31AMGlobeNewswireGalapagos receives milestone in osteoarthritis alliance with ServierLSE:GLPGGalapagos
      07/25/201412:00PMGlobeNewswireGalapagos creates new warrant planLSE:GLPGGalapagos
       Showing the most relevant articles for your search:LSE:GLPG